Cigna's Evernorth Health Allocates $3.5 Billion to Shields Health Solutions
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 02 2025
0mins
Evernorth's Investment: Evernorth Health Services, a subsidiary of The Cigna Group, has announced a $3.5 billion investment in Shields Health Solutions, which is now a standalone company following its acquisition by Sycamore Partners.
Financial Impact: The investment is structured as preferred stock and is not expected to significantly affect The Cigna Group's adjusted EPS guidance for 2025, which remains at a minimum of $29.60.
Analyst Views on CI
Wall Street analysts forecast CI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CI is 337.60 USD with a low forecast of 294.00 USD and a high forecast of 378.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
13 Buy
2 Hold
0 Sell
Strong Buy
Current: 277.940
Low
294.00
Averages
337.60
High
378.00
Current: 277.940
Low
294.00
Averages
337.60
High
378.00
About CI
The Cigna Group is a global health company. The Company has two growth platforms: Evernorth Health Services and Cigna Healthcare. Evernorth Health Services includes its Pharmacy Benefit Services and Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the healthcare system to work better and help people live richer, healthier lives. Cigna Healthcare includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical plan services and coordinated solutions to clients and customers. Its Other Operations include corporate-owned life insurance (COLI), the Company's run-off operations and other non-strategic businesses. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, and clinical programs to help its clients.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.





